Tag: percutaneous coronary intervention (PCI)

1. Patients with severely reduced left ventricular ejection fraction with left main, left anterior descending, or multivessel disease who underwent percutaneous coronary intervention demonstrated higher rates of mortality and major adverse cardiovascular events compared to those who underwent coronary artery bypass grafting. Evidence Rating Level: 2 (Good) There is insufficient evidence in...
1. In this modern population of Canadian patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), the rates of major adverse cardiovascular events (MACE) at 1 year follow-up were the same in groups treated with ticagrelor or clopidogrel. Ticagrelor was linked with a higher risk of...
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level:...
1. Colchicine given to patients after a myocardial infarction led to a significantly lower risk of death from cardiovascular causes, resuscitations, myocardial infarctions, stroke, and hospitalizations for angina. 2. The main adverse events from colchicine, as compared to placebo, were diarrhea, nausea, and pneumonia. Evidence Rating Level: 1 (Excellent) Study Rundown: The American...
1. Colchicine given to patients after a myocardial infarction led to a significantly lower risk of death from cardiovascular causes, resuscitations, myocardial infarctions, stroke, and hospitalizations for angina. 2. The main adverse events from colchicine, as compared to placebo, were diarrhea, nausea, and pneumonia. Evidence Rating Level: 1 (Excellent) Study Rundown: The...
1. In patients with STEMI and multivessel coronary artery disease, those randomized to the complete revascularization group experienced lower rates of cardiovascular death or myocardial infarction (MI) at 3 years compared to patients who were randomized to the culprit-lesion-only percutaneous coronary intervention group. 2. Both groups experienced similar rates of...
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial 1. Bleeding after percutaneous coronary intervention (PCI) was more common in women, but the effect of two antiplatelet strategies on death and new Q-wave myocardial infarction following PCI did...
1. Patients with obesity undergoing percutaneous coronary intervention are typically younger with more cardiovascular risk factors, but may be less likely to experience procedural complications, short-term and long-term adverse outcomes, with the exception of patients considered extremely obese Evidence Rating Level: 2 (Good) It has been well established that obesity is...
1. In patients with STEMI and multivessel coronary artery disease, those randomized to the complete revascularization group experienced lower rates of cardiovascular death or myocardial infarction (MI) at 3 years compared to patients who were randomized to the culprit-lesion-only percutaneous coronary intervention group. 2. Both groups experienced similar rates of...
PD-1 blockade in advanced adrenocortical carcinoma 1. Pembrolizumab may provide clinically meaningful anti-tumor activity in the setting of adrenocortical carcinoma, particularly in tumors characterized by microsatellite instability and/or mismatch repair  Evidence Rating Level: 2 (Good) Adrenocortical carcinomas (ACC) are rare and typically carry a poor prognosis, with the majority of patients presenting...